RANKL targeting—via genetic deletion or antibody neutralization—reverses bone loss, restores muscle function, and extends lifespan in a mouse model of Hutchinson-Gilford progeria. This suggests RANKL inhibition may address the accelerated tissue degeneration characteristic of this premature aging syndrome.
Key Points
- RANKL inhibition restored bone mass in long bones and vertebrae
- Treatment improved grip strength, endurance, and reduced muscle fibrosis
- Lifespan extension observed with both genetic and pharmacological approaches
Longevity Analysis
The convergence of structural integrity, muscular capacity, and survival extension in response to a single molecular target demonstrates how interference with a central regulatory pathway can coordinate benefits across multiple tissue systems. Bone loss and muscle wasting are hallmarks of aging and accelerated senescence; their simultaneous improvement through RANKL targeting suggests that addressing the cell-autonomous and systemic signals driving tissue resorption may offer a rational entry point for interventions in both progeria and age-related degeneration. The translation from genetic proof-of-concept to pharmacological agent (antibody) strengthens the case for clinical exploration.
Original published by Wiley Aging Cell, by Sandra Freitas‐Rodríguez, Alejandra Valle‐Cao, Francisco Rodríguez, Manuel Fernández‐Sanjurjo, Benjamín Fernández‐García, Vanessa Loredo, María Teresa Fernández‐García, Carmen Fiuza‐Luces, Alejandro Lucia, Carlos López‐Otín, Alejandro López‐Soto, Alicia R. Folgueras .